Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with GP vs TPC in NPC with Bone Metastases
NCT06383780Phase 3Recruiting
- Start
- May 2024
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tislelizumab in nasopharyngeal carcinoma (NPC). Started May 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06383780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06383780.